Analyst consensus rating
Adial Pharmaceuticals Analyst Rating: none
Direct answer
Adial Pharmaceuticals's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.33.
Forecast evidence checked October 27, 2026.
Get free Adial Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.71
- Average price target
- $8.33
- High price target
- $11.00
- Low price target
- $6.00
- Low target gap
- +61.7%
- Target upside
- +124.6%
- High target gap
- +196.5%
- Target range width
- 134.8%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Adial Pharmaceuticals?
Adial Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $8.33.
How far are Adial Pharmaceuticals's low and high targets from the recorded price?
The low target implies +61.7%, while the high target implies +196.5%.
How many analysts are included in Adial Pharmaceuticals's consensus?
The verified consensus includes 3 analysts.
How is Adial Pharmaceuticals's target upside or downside calculated?
The average target of $8.33 is divided by the recorded price of $3.71, then one is subtracted to produce +124.6%. This does not guarantee a future return.
When was Adial Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.